Skip to main content

Advertisement

SpringerLink
Log in

Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Four years after the latest edition, the 2015 non-ST-segment elevation acute coronary syndromes guidelines of the European Society of Cardiology have been published. Novel aspects include a new diagnostic algorithm for non-ST-segment elevation myocardial infarction using high-sensitivity cardiac troponins as well as guidance on cardiac rhythm monitoring duration. A large section is dedicated to antiplatelet therapy including initiation and duration of dual-antiplatelet therapy as well as the management of patients requiring, at the same time, long-term oral anticoagulation. New sections include the management of antiplatelet agent in patients requiring coronary artery bypass surgery and of acute bleeding events related to antiplatelet agents, vitamin K antagonist (VKA), and non-VKA oral anticoagulant drugs. Current evidence supports the radial access over the femoral one for coronary angiography and percutaneous revascularization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance,•• Of major importance

  1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2011;32:2999–3054. This is the 2011 version of the ESC guidelines on non-ST-elevation acute coronary syndromes.

  2. Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart J 2015. These guidelines represent the bases of the current manuscript.

  3. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–67.

    Article  PubMed  Google Scholar 

  4. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999–1010. This is the first randomized controlled trial that has addressed the value of P2Y12 pretreatment in acute coronary syndrome patients undergoing percutaneous coronary intervention.

  5. Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomized controlled trials. BMJ. 2015;350:h1618.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart J 2015.

  7. Valgimigli M, Gagnor A, Calabro P et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015. This randomized controlled trial, together with the meta-analysis included in the same paper, established the superiority of the radial access over the femoral one for coronary angiography and percutaneous coronary interventions in acute coronary syndromes.

  8. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–15.

    Article  CAS  PubMed  Google Scholar 

  9. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47.

    Article  PubMed  Google Scholar 

  10. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England J Med 2015.

  11. Mueller C, Patrono C, Valgimigli M et al. Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. European Heart J 2015. This is a companion manuscript to the 2015 ESC NSTE-ACS guidelines and give practical guidance on the management of individual patients based on the guidelines.

  12. Collet JP, Roffi M, Mueller C et al. Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation†. European Heart J 2015. This is a companion manuscript to the 2015 ESC NSTE-ACS guidelines and give practical guidance on the management of individual patients based on the guidelines.

  13. Valgimigli M, Patrono C, Collet JP et al. Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart J 2015. This is a companion manuscript to the 2015 ESC NSTE-ACS guidelines and give practical guidance on the management of individual patients based on the guidelines.

  14. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–79. This is a consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndromes and/or undergoing percutaneous coronary or valve interventions.

Download references

Acknowledgments

The content of this manuscript does not necessarily represent the view of the 2015 ESC NSTE-ACS guideline Task Force or the ESC Practice Guideline Committee.

Author information

Authors and Affiliations

  1. Division of Cardiology, Interventional Cardiology Unit, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, 1211, Geneva 14, Switzerland

    Marco Roffi & Baris Gencer

  2. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

    Robert F. Storey

  3. Institute of Cardiology, Catholic University School of Medicine, Rome, Italy

    Felicita Andreotti

  4. Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy

    Carlo Patrono

Authors
  1. Marco Roffi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baris Gencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert F. Storey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Felicita Andreotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlo Patrono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Roffi.

Ethics declarations

Conflict of Interest

Marco Roffi reports institutional research grants from Abbott Vascular, Biotronik, Biosensor, Medtronic, and Boston Scientific and personal fees from AstraZeneca related to NSTEMI guidelines talks.

Robert F. Storey reports grants, personal fees, and other from AstraZeneca; personal fees and non-financial support from Aspen; personal fees from PlaqueTec; personal fees from The Medicines Company; personal fees from Thermo Fisher Scientific; grants and personal fees from Merck; personal fees from Correvio; personal fees from Roche; personal fees from Regeneron; personal fees from Sanofi Aventis; personal fees and non-financial support from Accumetrics; and personal fees from Daiichi Sankyo/Eli Lilly. In addition, Dr. Storey is an inventor (but not the owner) of a pending patent related to study results.

Felicita Andreotti reports personal fees and non-financial support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Eli Lilly, and Pfizer that represent potential conflicts of interest.

Carlo Patrono reports grants from Bayer AG and personal fees from Bayer AG and is a member of the Scientific Advisory Board for the Aspirin Foundation.

Baris Gencer declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roffi, M., Gencer, B., Storey, R.F. et al. Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines. Curr Cardiol Rep 18, 48 (2016). https://doi.org/10.1007/s11886-016-0722-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0722-0

Keywords

Search

Navigation